Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2004 1
2005 1
2006 4
2007 4
2008 3
2009 6
2010 6
2011 5
2012 1
2013 4
2014 3
2015 28
2016 4
2017 11
2018 7
2019 5
2020 7
2021 12
2022 5
2023 4
2024 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023.
Peris K, Fargnoli MC, Kaufmann R, Arenberger P, Bastholt L, Seguin NB, Bataille V, Brochez L, Del Marmol V, Dummer R, Forsea AM, Gaudy-Marqueste C, Harwood CA, Hauschild A, Höller C, Kandolf L, Kellerners-Smeets NWJ, Lallas A, Leiter U, Malvehy J, Marinović B, Mijuskovic Z, Moreno-Ramirez D, Nagore E, Nathan P, Stratigos AJ, Stockfleth E, Tagliaferri L, Trakatelli M, Vieira R, Zalaudek I, Garbe C; EADO”A, EDF”B, ESTRO”C, UEMS”D and EADV”E. Peris K, et al. Among authors: gaudy marqueste c. Eur J Cancer. 2023 Oct;192:113254. doi: 10.1016/j.ejca.2023.113254. Epub 2023 Jul 28. Eur J Cancer. 2023. PMID: 37604067 Free article. Review.
Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt NM, Oh ST, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall AT, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti MP, Bidollari I, Lin HM, Sulllivan E, Mar B, Scherber R, Roche M, Akin C, Maurer M. Gotlib J, et al. Among authors: gaudy marqueste c. NEJM Evid. 2023 Jun;2(6):EVIDoa2200339. doi: 10.1056/EVIDoa2200339. Epub 2023 May 23. NEJM Evid. 2023. PMID: 38320129 Clinical Trial.
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J; CheckMate 067 Investigators. Wolchok JD, et al. Among authors: gaudy marqueste c. N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2407417. Online ahead of print. N Engl J Med. 2024. PMID: 39282897
Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes.
Polivka L, Madrange M, Bulai-Livideanu C, Barete S, Ballul T, Neuraz A, Greco C, Agopian J, Brenet F, Dubreuil P, Burdet C, Lemal R, Tournilhac O, Terriou L, Launay D, Bouillet L, Gourguechon C, Damaj G, Frenzel L, Meni C, Bouktit H, Collange AF, Gaudy-Marqueste C, Gousseff M, Le Mouel E, Hamidou M, Neel A, Ranta D, Jaussaud R, Guilpain P, Canioni D, Molina TJ, Bruneau J, Lhermitte L, Garcelon N, Javier RM, Pelletier F, Castelain F, Retornaz F, Cabrera Q, Zunic P, Gourin MP, Wierzbicka-Hainaut E, Viallard JF, Lavigne C, Hoarau C, Durieu I, Heiblig M, Dimicoli-Salazar S, Torregrosa-Diaz JM, Soria A, Arock M, Lortholary O, Bodemer C, Hermine O, Rossignol J; CEREMAST network. Polivka L, et al. Among authors: gaudy marqueste c. J Allergy Clin Immunol. 2024 Jan;153(1):349-353.e4. doi: 10.1016/j.jaci.2023.08.015. Epub 2023 Aug 24. J Allergy Clin Immunol. 2024. PMID: 37633651 Free article.
Molecular characterization of fast-growing melanomas.
Gaudy-Marqueste C, Macagno N, Loundou A, Pellegrino E, Ouafik L, Budden T, Mundra P, Gremel G, Akhras V, Lin L, Cook M, Kumar R, Grob JJ, Nagore E, Marais R, Virós A. Gaudy-Marqueste C, et al. J Am Acad Dermatol. 2022 Feb;86(2):312-321. doi: 10.1016/j.jaad.2021.07.011. Epub 2021 Jul 16. J Am Acad Dermatol. 2022. PMID: 34280484
Urticaria and quality of life.
Grob JJ, Gaudy-Marqueste C. Grob JJ, et al. Among authors: gaudy marqueste c. Clin Rev Allergy Immunol. 2006 Feb;30(1):47-51. doi: 10.1385/CRIAI:30:1:047. Clin Rev Allergy Immunol. 2006. PMID: 16461995 Review.
Nodular Melanoma: A Histopathologic Entity?
Green AC, Viros A, Hughes MCB, Gaudy-Marqueste C, Akhras V, Cook MG, Marais R. Green AC, et al. Among authors: gaudy marqueste c. Acta Derm Venereol. 2018 Apr 16;98(4):460-462. doi: 10.2340/00015555-2855. Acta Derm Venereol. 2018. PMID: 29182796 Free article. No abstract available.
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.
Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance AM, Daud AI, Hamid O, Larkin J, Yao L, Singh R, Lal R, Robert C. Long GV, et al. Among authors: gaudy marqueste c. Ann Oncol. 2024 Sep 15:S0923-7534(24)03910-3. doi: 10.1016/j.annonc.2024.08.2330. Online ahead of print. Ann Oncol. 2024. PMID: 39306585
Ultraviolet light-induced collagen degradation inhibits melanoma invasion.
Budden T, Gaudy-Marqueste C, Porter A, Kay E, Gurung S, Earnshaw CH, Roeck K, Craig S, Traves V, Krutmann J, Muller P, Motta L, Zanivan S, Malliri A, Furney SJ, Nagore E, Virós A. Budden T, et al. Among authors: gaudy marqueste c. Nat Commun. 2021 May 12;12(1):2742. doi: 10.1038/s41467-021-22953-z. Nat Commun. 2021. PMID: 33980846 Free PMC article.
Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: A nationwide French pilot study.
Moraly J, Rossignol J, Rouzaud C, Gabas T, Bouktit H, Lhermitte L, Canioni D, Fraitag S, Bruneau J, Barete S, Suarez F, Ballul T, Meni C, Polivka L, Terriou L, Launay D, Bouillet L, Gaudy-Marqueste C, Gousseff M, Le Mouel E, Neel A, Ranta D, Jaussaud R, Guilpain P, Frenzel L, Agopian J, Dubreuil P, Greco C, Dimicoli-Salazar S, Heiblig M, Gourguechon C, Tournilhac O, Javier RM, Castelain F, Cabrera Q, Gourin MP, Wierzbicka-Hainaut E, Torregrosa-Diaz JM, Bulai C, Lavigne C, Hoarau C, Arock M, Damaj G, Lortholary O, Hermine O; CEREMAST network. Moraly J, et al. Among authors: gaudy marqueste c. Am J Hematol. 2024 Jun;99(6):1095-1102. doi: 10.1002/ajh.27323. Epub 2024 Apr 6. Am J Hematol. 2024. PMID: 38581211
121 results